Although direct correlation of Gal-3 levels with clinical symptoms was not established, some other molecular mechanisms involved in Gal-3-dependent regulation could preserve cognitive potentials in patients with schizophrenia. This evidence concerns the gene LGALS3 and schizophrenia.